DEPOSIT AGREEMENTDeposit Agreement • June 1st, 2020 • Calliditas Therapeutics AB • Pharmaceutical preparations • Delaware
DEPOSIT AGREEMENT, dated as of ___________, 2020, by and among (i) Calliditas Therapeutics AB, a company organized under the laws of the Kingdom of Sweden, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
CREDIT AGREEMENT Dated as of December 27, 2023 among CALLIDITAS THERAPEUTICS AB, as the Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER, as the Guarantors, ATHYRIUM OPPORTUNITIES IV CO-INVEST 1 LP, as the Administrative Agent and THE LENDERS FROM TIME...Credit Agreement • April 24th, 2024 • Calliditas Therapeutics AB • Pharmaceutical preparations • New York
This CREDIT AGREEMENT is entered into as of December 27, 2023 among CALLIDITAS THERAPEUTICS AB, a Swedish public limited liability company with Swedish registration number 556659-9766 (the “Borrower”), the Guarantors (defined herein), the Lenders (defined herein) and ATHYRIUM OPPORTUNITIES IV CO-INVEST 1 LP, as the Administrative Agent.
EMPLOYMENT AGREEMENTEmployment Agreement • May 14th, 2020 • Calliditas Therapeutics AB • Pharmaceutical preparations
Between Calliditas Therapeutics AB, 556659-9766 ("The Company"), Wallingatan 26B, 111 24 Stockholm and Frank Bringstrup [***] has signed the following employment contract.
EMPLOYMENT AGREEMENTEmployment Agreement • May 14th, 2020 • Calliditas Therapeutics AB • Pharmaceutical preparations
March 1, 2019 Mr. Andrew B. Udell Re: Employment AgreementBonus Agreement • May 14th, 2020 • Calliditas Therapeutics AB • Pharmaceutical preparations • Connecticut
This letter confirms our understanding and agreement with respect to (i) your future employment by Calliditas Therapeutics US, Inc. (the "Company"), (ii) your agreement not to compete with the Company, or any present or future parent, subsidiary or affiliate of the Company (each, a ''Company Affiliate" and collectively, together with the Company, the "Company Group"), (iii) your agreement to protect and preserve information and property which is confidential and proprietary to the Company Group, and (iv) your agreement with respect to the ownership of inventions, ideas, copyrights and patents which may be used in the business of the Company Group (the terms and conditions agreed to in this letter are hereinafter referred to as the "Agreement"). In consideration of the mutual promises and covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, we have agreed as follows:
EMPLOYMENT AGREEMENT BETWEEN PHARMALINK AB AND JOHAN HÄGGBLAD May 1, 2017 EMPLOYMENT AGREEMENTEmployment Agreement • May 14th, 2020 • Calliditas Therapeutics AB • Pharmaceutical preparations
CONSULTING AGREEMENTConsulting Agreement • May 14th, 2020 • Calliditas Therapeutics AB • Pharmaceutical preparations
Calliditas Therapeutics AB, a corporation duly organized and existing under the laws of Sweden and having its principal place of business at Wallingatan 26b, SE-111 24 Stockholm, Sweden (“CALLIDITAS”), and
EMPLOYMENT AGREEMENT BETWEEN PHARMALINK AB AND RENEE AGUlAR-LUCANDER May 1, 2017 EMPLOYMENT AGREEMENTEmployment Agreement • May 14th, 2020 • Calliditas Therapeutics AB • Pharmaceutical preparations
●] Common Shares (Quota Value SEK 0.04 Per Share) (including [●] American Depositary Shares, each Representing Two Common Shares) Underwriting AgreementUnderwriting Agreement • June 1st, 2020 • Calliditas Therapeutics AB • Pharmaceutical preparations • New York
This letter is being delivered to you in connection with the offering by Calliditas Therapeutics AB (the “Company”) of (i) common shares, quota value SEK 0.04 per share (the “Common Shares”), and (ii) Common Shares to be delivered in the form of American Depositary Shares (“ADSs”), of the Company, and the lock-up letter dated ______, 20__ (the “Lock-up Letter”), executed by you in connection with such offering, and your request for a [waiver] [release] dated [insert date], 20__, with respect to [__ Common Shares (the “Lock-Up Shares”)] [__ ADSs (the “Lock-Up ADSs”)].
CONTRACT OF EMPLOYMENT PRIVATE AND CONFIDENTIAL CHIEF MEDICAL OFFICERCalliditas Therapeutics AB • January 26th, 2021 • Pharmaceutical preparations • England and Wales
This contract sets out your main terms and conditions of employment with the Company unless otherwise agreed in writing. This contract supersedes any previous agreements (including any custom and practice) and shall prevail in the event of any inconsistency of terms.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER...Calliditas Therapeutics AB • April 24th, 2024 • Pharmaceutical preparations
With effect from the date stated at the start of this Agreement (the “Effective Date”), the parties have agreed to the following terms:
Board LTIP 2022 in Calliditas Therapeutics AB (publ) GRANT NOTICE & AGREEMENTAgreement • April 26th, 2023 • Calliditas Therapeutics AB • Pharmaceutical preparations
On 19 May 2022, the annual general meeting in Calliditas Therapeutics AB (publ) (the “Company”) resolved to introduce a long-term performance-based incentive program for members of the Board of Directors (“Board LTIP 2022”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER...Product Agreement • April 24th, 2024 • Calliditas Therapeutics AB • Pharmaceutical preparations
This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated December 30, 2020 between Patheon Pharmaceuticals Inc. and Calliditas Therapeutics AB (the “Master Agreement”), and is entered into on December 30, 2020 (the “Effective Date”) between Patheon Pharmaceuticals Inc., a corporation existing under the laws of the State of Delaware, with its principal place of business at 2110 East Galbraith Road, Cincinnati, OH 45237 (“Patheon”) and Calliditas Therapeutics AB, a company existing under the laws of Sweden, with its principal place of business at Kungsbron 1, C8, SE-111 22 Stockholm (“Client”). For the purpose of this Product Agreement, references in the Master Agreement to “Patheon” and “Client” mean the entities defined respectively as Patheon and Client in this Product Agreement.
Page 1 ( 5 ) No.: 101940-2182-04 TENANCY AGREEMENT FOR NON-RESIDENTIAL PREMISES The undersigned parties have concluded the following Tenancy Agreement on this date. A cross in a box means that the accompanying text applies Terminalen 3 termination/...Calliditas Therapeutics AB • February 4th, 2020 • Pharmaceutical preparations
LICENSE AGREEMENT regarding NEFECON™ between CALLIDITAS THERAPEUTICS AB (PUBL) and EVEREST MEDICINES II LIMITEDLicense Agreement • February 4th, 2020 • Calliditas Therapeutics AB • Pharmaceutical preparations • England and Wales
Supplemental Agreement and First Amendment to License Agreement regarding NEFECONTM between Calliditas Therapeutics AB (Publ) and Everest Medicines II LimitedSupplemental Agreement • April 27th, 2022 • Calliditas Therapeutics AB • Pharmaceutical preparations
This SUPPLEMENTAL AGREEMENT AND FIRST AMENDMENT TO THE LICENSE AGREEMENT REGARDING NEFECONTM (this “First Amendment”) is made and entered into by and between Calliditas Therapeutics AB (Publ), corp. reg. no. 556659-9766, with a registered office at PO Box 70351, SE-107 24 Stockholm, Sweden (“Licensor” or “Calliditas”), and Everest Medicines II Limited, an exempted company organized and existing under the laws of Cayman Islands, with a registered office at Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 (“Licensee”). Licensor and Licensee may be referred herein individually as a “Party”, and collectively as the “Parties”.
INTELLECTUAL PROPERTY SECURITY AGREEMENTIntellectual Property Security Agreement • July 19th, 2021 • Calliditas Therapeutics AB • Pharmaceutical preparations • New York
THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of July 16, 2021, is entered into by and among (1) CALLIDITAS THERAPEUTICS AB (the “Grantor”), a company incorporated in Sweden, and (2) KREOS CAPITAL VI (UK) LIMITED (“Lender 1”), a company incorporated in England and Wales, and KREOS CAPITAL 2020 OPPORTUNITY (UK) LIMITED (“Lender 2”), a company incorporated in England and Wales, and each of the other entities which becomes a party to the Loan Agreement (as defined below) as a lender from time to time (each of the foregoing described in this clause (2), including Lender 1 and Lender 2, each a “Lender” and collectively, the “Lenders”).
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Commercialization Agreement • July 23rd, 2021 • Calliditas Therapeutics AB • Pharmaceutical preparations • England and Wales
This COMMERCIALIZATION AGREEMENT (this “Agreement”) is made and effective as of July 21, 2021 (the “Effective Date”) by and among Calliditas Therapeutics AB, a company organized under the laws of Sweden, with company registration number 556659-9766 and its registered office and mailing address at PO Box 70351, SE-107 24 Stockholm, Sweden and its principal office and address for courier delivery at Kungsbron 1, C8, SE-111 22 Stockholm, Sweden (“Calliditas”) and STADA Arzneimittel AG, a company organized under the laws of Germany, with a registered office at Stadastrasse 2-18, 61118 Bad Vilbel, Germany (“Partner”) (each of Calliditas and Partner being a “Party,” and collectively, the “Parties”).
SHARE PURCHASE AGREEMENTShare Purchase Agreement • January 26th, 2021 • Calliditas Therapeutics AB • Pharmaceutical preparations
LICENSE AGREEMENT between CALLIDITAS THERAPEUTICS AB (PUBL) and VIATRIS PHARMACEUTICALS JAPAN INC.License Agreement • April 26th, 2023 • Calliditas Therapeutics AB • Pharmaceutical preparations • New York
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
